The international pharmaceutical business environment continues to develop at a rapid rate. Increasing interactions between economies, particularly between North America, Europe and Asia, have raised many important issues regarding transport infrastructure, logistics and broader supply chain management (SCM). The potential exists to further
enhance shareholder value through enhanced trade, provided that these issues are addressed in a logical and systematic manner.